Caris GPSai™, from Caris Life Sciences®, provides information on the cancer’s anatomic site of origin, in addition to the biomarker data from MI profiling, to guide more precise and personalized treatment options. Caris GPSai analyzes a tumor’s molecular signature and provides the prevalence of that signature in the Caris genomic (DNA) and transcriptomic (RNA) database across 21 cancer categories. This new tool is intended to provide additional insight to help oncologists better manage cancers of unknown primary (CUP) or cases with atypical clinical presentation or clinical ambiguity, as identified by the ordering physician.
Caris GPSai can be added to any solid tumor order by selecting the appropriate box on the Caris requisition. Results for Caris GPSai will be presented in the final Caris report. These results will provide additional insight by assessing how closely tumors match the genomic and transcriptomic signatures of 21 cancer types to help you make more informed treatment decisions.
The below case study shows how Caris GPSai can be pivotal in identifying primary cancer sites. Caris GPSai provides additional insight to help oncologists better manage cancers of unknown primary (CUP) or cases with atypical clinical presentation.
To view the case study please click on the corresponding pages below.
You can also download a copy of the case study by clicking here.